TWI632158B - ＩｇＧ刺激之周圍神經再髓鞘形成 - Google Patents

ＩｇＧ刺激之周圍神經再髓鞘形成 Download PDF

Info

Publication number
TWI632158B
TWI632158B TW102107471A TW102107471A TWI632158B TW I632158 B TWI632158 B TW I632158B TW 102107471 A TW102107471 A TW 102107471A TW 102107471 A TW102107471 A TW 102107471A TW I632158 B TWI632158 B TW I632158B
Authority
TW
Taiwan
Prior art keywords
igg
neuropathy
ivig
myelin
administered
Prior art date
Application number
TW102107471A
Other languages
English (en)
Chinese (zh)
Other versions
TW201400502A (zh
Inventor
派翠克 克里
尼薇那 策克瓦
漢斯 彼得 哈筒
科麗娜 赫曼
伯吉特 瑪莉亞 瑞伯特
漢斯 彼得 史瓦茲
哈穆 赫里基
薩巴斯提恩 本克
Original Assignee
巴克斯歐塔公司
巴克斯歐塔有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯歐塔公司, 巴克斯歐塔有限公司 filed Critical 巴克斯歐塔公司
Publication of TW201400502A publication Critical patent/TW201400502A/zh
Application granted granted Critical
Publication of TWI632158B publication Critical patent/TWI632158B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
TW102107471A 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成 TWI632158B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29

Publications (2)

Publication Number Publication Date
TW201400502A TW201400502A (zh) 2014-01-01
TWI632158B true TWI632158B (zh) 2018-08-11

Family

ID=47884569

Family Applications (3)

Application Number Title Priority Date Filing Date
TW102107471A TWI632158B (zh) 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成
TW106122004A TWI700297B (zh) 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成
TW107124197A TW201838654A (zh) 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW106122004A TWI700297B (zh) 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成
TW107124197A TW201838654A (zh) 2012-02-29 2013-03-01 ＩｇＧ刺激之周圍神經再髓鞘形成

Country Status (21)

Country Link
US (5) US8986670B2 (cg-RX-API-DMAC7.html)
EP (2) EP2820042B1 (cg-RX-API-DMAC7.html)
JP (3) JP6335800B2 (cg-RX-API-DMAC7.html)
KR (3) KR102170615B1 (cg-RX-API-DMAC7.html)
CN (4) CN104302666A (cg-RX-API-DMAC7.html)
AR (2) AR090211A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013203088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021240A2 (cg-RX-API-DMAC7.html)
DK (2) DK2820042T3 (cg-RX-API-DMAC7.html)
EA (2) EA032000B1 (cg-RX-API-DMAC7.html)
ES (2) ES2755056T3 (cg-RX-API-DMAC7.html)
FI (1) FI3590960T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248534A1 (cg-RX-API-DMAC7.html)
IL (3) IL274512B2 (cg-RX-API-DMAC7.html)
MX (2) MX369444B (cg-RX-API-DMAC7.html)
NZ (1) NZ629867A (cg-RX-API-DMAC7.html)
PL (2) PL3590960T3 (cg-RX-API-DMAC7.html)
PT (2) PT3590960T (cg-RX-API-DMAC7.html)
SG (1) SG11201405302WA (cg-RX-API-DMAC7.html)
TW (3) TWI632158B (cg-RX-API-DMAC7.html)
WO (1) WO2013130826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
CN111655336A (zh) 2017-11-17 2020-09-11 纽约州立大学研究基金会 使用x射线微束辐射治疗受损周围神经的方法
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
WO2025005230A1 (ja) * 2023-06-30 2025-01-02 富士フイルム株式会社 神経炎症の細胞間相互作用を評価する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
BR9911131A (pt) 1998-06-09 2001-03-06 Statens Seruminstitut Processo para produção de imunoglobulinas para administração intravenosa e outros produtos de imunoglobulina
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
MXPA02011163A (es) * 2000-05-10 2004-08-19 Mayo Foundation Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
RU2412721C2 (ru) 2003-01-24 2011-02-27 Элан Фармасьютикалз Инк. Применение ремиелинизирующего средства для стимуляции нервных клеток при демиелинизирующем заболевании
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
GEP20135853B (en) * 2007-02-02 2013-06-25 Univ Pierre And Marie Curie Method of myelination and oligodendrocyte differentiation promotion
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Odaka, Masaaki MD, PhD et al., Journal of CLINICAL NEUROMUSCULAR DISEASE Volume 8, Number 4 June 2007, p207-211. *
Stübgen JP, J Neurol Sci. 2011 Aug 15;307(1-2):1-8.
Vargas ME et al., Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11993-8.
Vargas ME et al., Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11993-8. Stübgen JP, J Neurol Sci. 2011 Aug 15;307(1-2):1-8. *

Also Published As

Publication number Publication date
AU2013203088B2 (en) 2015-12-03
TW201736398A (zh) 2017-10-16
KR20220045087A (ko) 2022-04-12
US10494418B2 (en) 2019-12-03
SG11201405302WA (en) 2014-09-26
DK2820042T3 (da) 2019-10-28
FI3590960T3 (fi) 2023-04-25
ES2755056T3 (es) 2020-04-21
PT2820042T (pt) 2019-10-31
AU2018200026B2 (en) 2019-12-05
MX2014010387A (es) 2015-09-25
US20200216518A1 (en) 2020-07-09
JP6637934B2 (ja) 2020-01-29
AR117207A2 (es) 2021-07-21
BR112014021240A2 (pt) 2018-09-18
JP2020059705A (ja) 2020-04-16
TW201400502A (zh) 2014-01-01
IL234303B (en) 2020-09-30
NZ629867A (en) 2016-09-30
IL274512B2 (en) 2024-07-01
KR20140134690A (ko) 2014-11-24
AU2016201137A1 (en) 2016-03-10
PL3590960T3 (pl) 2023-07-17
WO2013130826A3 (en) 2013-12-05
CN109966488A (zh) 2019-07-05
PL2820042T3 (pl) 2020-03-31
IL274512A (en) 2020-06-30
EP3590960B1 (en) 2023-03-29
HK1206035A1 (en) 2015-12-31
US20180291087A1 (en) 2018-10-11
US8986670B2 (en) 2015-03-24
CN104302666A (zh) 2015-01-21
JP6979990B2 (ja) 2021-12-15
US20210300997A1 (en) 2021-09-30
CN107551269A (zh) 2018-01-09
US20150232536A1 (en) 2015-08-20
AU2016201137B2 (en) 2017-10-12
EA201892521A1 (ru) 2019-07-31
AR090211A1 (es) 2014-10-29
ES2943585T3 (es) 2023-06-14
AU2013203088A1 (en) 2013-09-19
MX369444B (es) 2019-11-08
MX2019012496A (es) 2020-01-20
IL277103B2 (en) 2025-07-01
EP3590960A1 (en) 2020-01-08
TWI700297B (zh) 2020-08-01
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
KR20200126005A (ko) 2020-11-05
IL277103A (en) 2020-10-29
PT3590960T (pt) 2023-04-18
KR102170615B1 (ko) 2020-10-28
AU2018200026A1 (en) 2018-01-25
EP2820042A2 (en) 2015-01-07
EP2820042B1 (en) 2019-07-24
JP2015508824A (ja) 2015-03-23
EA201400966A1 (ru) 2014-12-30
CN110343171A (zh) 2019-10-18
TW201838654A (zh) 2018-11-01
JP2018030856A (ja) 2018-03-01
US9834593B2 (en) 2017-12-05
IL274512B1 (en) 2024-03-01
EA032000B1 (ru) 2019-03-29
US20130224150A1 (en) 2013-08-29
JP6335800B2 (ja) 2018-05-30
IL277103B1 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
US20210300997A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
US20130302320A1 (en) Use of Semaphorin-4D Binding Molecules to Promote Neurogenesis Following Stroke
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
AU2021297152A1 (en) Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg